{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:04:26Z","timestamp":1793826266431,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clnesp.2026.103275","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:26:42Z","timestamp":1775690802000},"page":"103275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Triglyceride-related lipid changes in adults with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: A real-world cross-sectional study"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6053-7844","authenticated-orcid":false,"given":"E.","family":"Zamarr\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"P\u00e9rez Cuadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Baloira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Aguilera Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Palma Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gonz\u00e1lez P\u00e9rez de Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mariscal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"\u00c1lvarez-Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Prados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2026.103275_bib1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnesp.2026.103275_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib4","doi-asserted-by":"crossref","unstructured":"Kerem E, Orenti A, Adamoli A, Hatziagorou E, Naehrlich L, Sermet-Gaudelus I, et al. Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain. Eur Respir J. 202;63:2301241.","DOI":"10.1183\/13993003.01241-2023"},{"key":"10.1016\/j.clnesp.2026.103275_bib5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.medcli.2024.03.010","article-title":"Renal involvement in adults with cystic fibrosis: study of 89 patients","volume":"163","author":"Zamarr\u00f3n","year":"2024","journal-title":"Med Clin"},{"key":"10.1016\/j.clnesp.2026.103275_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/phar.2903","article-title":"Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis","volume":"44","author":"Lonabaugh","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clnesp.2026.103275_bib9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clnesp.2026.103275_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcf.2024.11.009","article-title":"Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"24","author":"Gramegna","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.freeradbiomed.2014.08.005","article-title":"Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis","volume":"76","author":"Reverri","year":"2014","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.clnesp.2026.103275_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12967-019-02139-4","article-title":"Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis","volume":"17","author":"Lai","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.clnesp.2026.103275_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcf.2012.03.006","article-title":"LDL-cholesterol and insulin are independently associated with body mass index in adult cystic fibrosis patients","volume":"11","author":"Coderre","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib14","doi-asserted-by":"crossref","first-page":"E795","DOI":"10.1152\/ajpendo.00293.2024","article-title":"Lipidome profile of cystic fibrosis related diabetes, type 1 and type 2 diabetes mellitus: potential links to inflammation and glucose and lipid metabolism","volume":"329","author":"Mingione","year":"2025","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clnesp.2026.103275_bib15","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnesp.2026.103275_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0045-2024","article-title":"New drugs, new challenges in cystic fibrosis care","volume":"33","author":"Fajac","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.clnesp.2026.103275_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0042-1758734","article-title":"Beyond the lungs-emerging challenges in adult cystic fibrosis care","volume":"44","author":"Mulrennan","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.clnesp.2026.103275_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68511-7","article-title":"Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"14","author":"Castaldo","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnesp.2026.103275_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00174-2023","article-title":"Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study","volume":"62","author":"Frost","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clnesp.2026.103275_bib20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): a timely and accurate diagnosis","volume":"22","author":"Castellani","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American college of cardiology solution set oversight committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clnesp.2026.103275_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.numecd.2021.11.005","article-title":"Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in the general population: a systematic review and meta-analysis of cohort studies","volume":"32","author":"Chen","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.clnesp.2026.103275_bib23","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jcf.2023.10.002","article-title":"Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis","volume":"22","author":"Despotes","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejim.2008.06.011","article-title":"Gender differences in the lipid profile of dyslipidemic subjects","volume":"20","author":"Kolovou","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clnesp.2026.103275_bib25","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1210\/jc.2018-01656","article-title":"Association between triglyceride level and glycemic control among insulin-treated patients with type 2 diabetes","volume":"104","author":"Zheng","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clnesp.2026.103275_bib26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jcf.2020.04.004","article-title":"Dyslipidemia is not associated with the development of glucose intolerance or diabetes in cystic fibrosis","volume":"19","author":"Colomba","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnesp.2026.103275_bib27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/ajcn\/75.6.1005","article-title":"Abnormal lipid concentrations in cystic fibrosis","volume":"75","author":"Figueroa","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnesp.2026.103275_bib28","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis 2 years after elexacaftor\/tezacaftor\/ivacaftor: promise-endo","volume":"110","author":"Chan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clnesp.2026.103275_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnesp.2026.103275_bib30","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1002\/ncp.11122","article-title":"Cystic fibrosis and fat malabsorption: pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy","volume":"39","author":"McDonald","year":"2024","journal-title":"Nutr Clin Pract"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726003712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726003712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:38:10Z","timestamp":1779413890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457726003712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S2405457726003712"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103275","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triglyceride-related lipid changes in adults with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: A real-world cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103275"}}